Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

30.11.16	BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 (PR Newswire)
30.11.16	Research Reports Coverage on Biotech Stocks -- Biogen, BioMarin Pharma, Seattle Genetics, and Grifols (PR Newswire)
07.11.16	Biogen & Ionis: SPINRAZA Meets Primary Endpoint In Phase 3 Study - Quick Facts (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)
28.10.16	Biogen Says FDA Accepts Its NDA For Nusinersen (RTTNews)
26.10.16	Biogen Inc. Q3 Profit Rises 10% (RTTNews)
15.09.16	Biogen Reveals Positive Result For Phase 3 Trial Of Zinbryta In MS Patients (RTTNews)
15.09.16	New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile (Businesswire)
14.09.16	Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials (RTTNews)
14.09.16	New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting (Businesswire)
31.08.16	Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab (Businesswire)
09.08.16	Biogen Says Bioverativ As Name Of New Hemophilia-Focused Company (RTTNews)
09.08.16	Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company (Businesswire)
05.08.16	The Race To Cure Spinal Muscular Atrophy (RTTNews)
03.08.16	WSJ : Biogen Draws Takeover Interest From Rival Drugmakers (RTTNews)
01.08.16	Biogen, Ionis: Nusinersen Meets Primary Endpoint At Interim Analysis Of Trial (RTTNews)
21.07.16	Biogen Sees FY16 EPS Above View; CEO To Resign; To Buy Back $5 Bln Shares (RTTNews)
21.07.16	Biogen Inc. Q2 Profit Advances 15% (RTTNews)
18.07.16	The World's Top Green Companies (RTTNews)
18.07.16	Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress (Businesswire)
18.07.16	Biogen: SB5 Accepted For Review By EMA - Quick Facts (RTTNews)
18.07.16	SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency (Businesswire)
05.07.16	Biogen And AbbVie's Once-Monthly ZINBRYTA Approved In EU To Treat MS (RTTNews)
05.07.16	Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis (Businesswire)
21.06.16	Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology (Businesswire)
09.06.16	Biogen : Data Shows Safety And Efficacy Of Anti-TNF Biosimilars Portfolio (RTTNews)
09.06.16	New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio (Businesswire)
08.06.16	ALDX Expects Data In Q3, CATB Tumbles On Study Data, Teva Gets FDA Panel Nod (RTTNews)
07.06.16	Biogen Says Opicinumab Missed Primary Endpoint; Stock Falls (RTTNews)
07.06.16	Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis (Businesswire)
01.06.16	Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program (Businesswire)
31.05.16	Biogen Gets Positive Opinion From CHMP On Tysabri - Quick Facts (RTTNews)
31.05.16	Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy (Businesswire)
30.05.16	FLIXABI, Biogen Infliximab Biosimilar Referencing Remicade, Approved In EU (RTTNews)
30.05.16	FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union (Businesswire)
30.05.16	AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June (RTTNews)
28.05.16	AbbVie, Biogen: FDA Approves Once-Monthly ZINBRYTA For Multiple Sclerosis (RTTNews)
13.05.16	Biogen Says Alprolix Approved In EU For Treatment Of Haemophilia B (RTTNews)
13.05.16	Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B (Businesswire)
03.05.16	Biogen Plans To Spin Off Its Hemophilia Business (RTTNews)
29.04.16	Biogen, AbbVie Get Positive Opinion From CHMP On Zinbryta - Quick Facts (RTTNews)
29.04.16	Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis (Businesswire)
21.04.16	Biogen Q1 Profit Up 18%, Beats Estimates (RTTNews)
21.04.16	Biogen Inc. Q1 Profit Advances 17% (RTTNews)
20.04.16	Biogen: New Data Shows ZINBRYTA Provides Improvements On Cognitive Outcomes (RTTNews)
20.04.16	Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action (Businesswire)
14.04.16	Biogen Joins in Celebration of World Hemophilia Day (Businesswire)
12.04.16	Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients (Businesswire)
01.04.16	FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion (Businesswire)
26.02.16	Sobi, Biogen Receive Positive Opinion From CHMP For Alprolix - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	536.80	1.09 %	K V
Roche Hldg G	253.10	0.68 %	K V
Nestle	76.26	0.55 %	K V
Sonova Hldg	305.80	0.39 %	K V
Givaudan	3’893.00	0.26 %	K V
Sika	227.60	-0.44 %	K V
Holcim	88.02	-0.45 %	K V
UBS Group	27.60	-0.58 %	K V
ABB	49.11	-0.87 %	K V
Logitech Intl	70.50	-2.06 %	K V

mehr

09:28		Schwache Performance in Frankfurt: TecDAX zum Start des Mittwochshandels schwächer
09:28		Handel in Frankfurt: LUS-DAX sackt zum Handelsstart ab
09:28		Schwacher Wochentag in Frankfurt: DAX verliert zum Start des Mittwochshandels
09:28		Aufschläge in Frankfurt: SDAX legt zum Start zu
09:28		Euro STOXX 50 aktuell: Euro STOXX 50 notiert zum Start im Minus
26.11.24		Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100
26.11.24		Dow Jones aktuell: Dow Jones zum Handelsende in Grün

09:28

Schwache Performance in Frankfurt: TecDAX zum Start des Mittwochshandels schwächer

09:28

Handel in Frankfurt: LUS-DAX sackt zum Handelsstart ab

09:28

Schwacher Wochentag in Frankfurt: DAX verliert zum Start des Mittwochshandels

09:28

Aufschläge in Frankfurt: SDAX legt zum Start zu

09:28

Euro STOXX 50 aktuell: Euro STOXX 50 notiert zum Start im Minus

26.11.24

Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100